ATHERSYS, INC / NEW
ATHERSYS, INC / NEW (ATHX): 1 pipeline candidate · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.1 months
0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for ATHERSYS, INC / NEWacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$1.0M
Quarterly Burn
$3.8M
Runway
1.1 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| multistem | Phase 2 |
Frequently asked questions
How many drug candidates are in ATHERSYS, INC / NEW's pipeline?
ATHERSYS, INC / NEW (ATHX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is ATHERSYS, INC / NEW's lead drug candidate?
ATHERSYS, INC / NEW's most advanced tracked candidate is multistem (Phase 2) for Traumatic injuries.
What is ATHERSYS, INC / NEW's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ATHERSYS, INC / NEW has approximately 1.1 months of cash runway.
Who is the CEO of ATHERSYS, INC / NEW?
Dear Fellow Stockholders is the chief executive officer of ATHERSYS, INC / NEW (ATHX).
Get the full picture on ATHERSYS, INC / NEW
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.